Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 7/20 | 0.54 |
| ▸ | CDK2 | P24941 | 6/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.54 |
| ▸ | GSK3A | P49840 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.54 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.54 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.54 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.54 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.54 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818827 | 0.91 | CDK2 (0.55) | IKBKBCDK2MAPK8MAPK9PRKD3 | |
| SCHEMBL3817051 | 0.89 | CDK2 (0.59) | IKBKBCDK2MAPK8MAPK9PRKD3 | |
| SCHEMBL3813008 | 0.87 | MAPK9 (0.71) | IKBKBCDK2MAPK8MAPK9PRKD3 | |
| SCHEMBL3811366 | 0.85 | MAPK8 (0.69) | IKBKBCDK2MAPK8MAPK9PRKD3 | |
| Hydrochloric Acid SCHEMBL2746007 | 0.84 | MAPK8 (0.68) | IKBKBCDK2MAPK8MAPK9PRKD3 | |
| SCHEMBL3812992 | 0.83 | MAPK8 (0.76) | IKBKBCDK2MAPK8MAPK9PRKD3 | |
| SCHEMBL2745813 | 0.83 | MAPK9 (0.57) | CDK2MAPK8MAPK9PRKD3MAP4K4 | |
| SCHEMBL2745991 | 0.82 | PRKD3 (0.50) | IKBKBCDK2MAPK8MAPK9PRKD3 | |
| SCHEMBL2745989 | 0.82 | PRKD3 (0.50) | IKBKBCDK2MAPK8MAPK9PRKD3 | |
| SCHEMBL12042804 | 0.82 | MAPK9 (0.59) | IKBKBCDK2MAPK8MAPK9PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| EP-1633758-B1 | IMIDAZOTHIAZOLES AND IMIDAZOXAZOLE DERIVATIVES AS INHIBITORS OF P38 | ARQULE INC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902192-B2 | Inhibitors of P38 and methods of using the same | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2251343-A1 | IMIDAZOTHIAZOLES AS P38-KINASE-INHIBITORS | ARQULE, INC. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | ARQULE, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501430-B2 | e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders | ARQULE, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281955-A1 | RAF inhibitors and their uses | ARQULE, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | ARQULE, INC. | 2007-11-22 | — | — | US | disclosed |
| WO-2007123892-A2 | RAF INHIBITORS AND THEIR USES | ARQULE INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270418-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK8, MAPK7 | IKBKB 78/4885CDK2 393/4885MAPK8 2/4885 |
| US-20070281955-A1 | RAF inhibitors and their uses | BRAF, RAF1, ARAF | IKBKB 421/4885CDK2 55/4885MAPK8 301/4885 |
| US-20090136499-A1 | RAF Inhibitors and Uses Thereof | BRAF, RAF1, ARAF | IKBKB 422/4885CDK2 86/4885MAPK8 298/4885 |
| US-20110301160-A1 | Inhibitors of P38 and Methods of Using the Same | MAPK1, MAPK7, MAPK8 | IKBKB 82/4885CDK2 367/4885MAPK8 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.